JMIR Aging - Search

View query in Help articles search

Field

e.g. mhealth

Operator

Field

Criteria

e.g. John Smith or 0000-0001-6479-5330

Exact Match for Criteria

Yes No

Search Results (1 to 10 of 1192 Results)

Download search results: CSV END BibTex RIS

Sort by:

Mobile Health Technology for Personalized Tobacco Cessation Support Among Cancer Survivors and Caregivers in Laos (Project SurvLaos): Protocol for a Pilot Randomized Controlled Trial

Phayvanh Keopaseuth, Phonepadith Xangsayarath, Shweta Kulkarni, Khatthanaphone Phandouangsy, Chanthavy Soulaphy, Phetsamone Alounlungsy, Vangnakhone Dittaphong, Dalouny Xayavong, Champadeng Vongdala, Latsamy Siengsounthone, Michael Businelle, Summer G Frank-Pearce, Damon J Vidrine, Jennifer I Vidrine, Thanh Cong Bui

JMIR Res Protoc 2025;14:e66517

Download Citation: END BibTex RIS

Download PDF Download XML

Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024

Amrutha S Alibilli, Vidur Jain, Heran Mane, Xiaohe Yue, Alexandria Ratzki-Leewing, Junaid S Merchant, Shaniece Criss, Quynh C Nguyen, Rozalina G McCoy, Thu T Nguyen

JMIR Infodemiology 2025;5:e73619

Download Citation: END BibTex RIS

Download PDF Download XML

A Supplemental Women’s Health Questionnaire for Women Veterans With Military Environmental Exposures: Project Development and Implementation

Leah N Eizadi, Mehret T Assefa, Jordan M Nechvatal, G Marina Veltkamp, Abou Ibrahim-Biangoro, Maheen M Adamson, Jennifer S Jennings

JMIR Form Res 2025;9:e73223

Download Citation: END BibTex RIS

Download PDF Download XML

Sodium Oxybate as a Potential New Treatment for Catatonia in Patients With Depression, Bipolar Disorder, or a Psychotic Disorder: Protocol for a Randomized Controlled Trial

It was administered in doses ranging between 0.01 and 0.1 g/kg, 3 times daily either orally or intravenously (equivalent to 2.4-24 g/d for an 80 kg patient). Among patients with schizophrenia and catatonia, approximately 30 participants, the study showed a reduction of catatonic symptoms ranging from 60% to 70%. Specifically, there were improvements in anxiety, agitation, and restlessness.

Lilian Bot, Josine G van Mill, Laetitia J C A Smarius, Adriaan W Hoogendoorn, Bram W C Storosum, Christiaan H Vinkers, Gabriel E Jacobs, Gert Jan Lammers, Hanna M Heller, Jantine C A Colen-de Koning, Joris J B van der Vlugt, Marloes S Oudijn, Martijn S van Noorden, Pierre M Bet, Rolf Fronczek, Heleen S van der Heijden, Sjors M M Lange, Ysbrand D van der Werf, Eric R van Exel